DE60219469D1 - Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika - Google Patents

Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika

Info

Publication number
DE60219469D1
DE60219469D1 DE60219469T DE60219469T DE60219469D1 DE 60219469 D1 DE60219469 D1 DE 60219469D1 DE 60219469 T DE60219469 T DE 60219469T DE 60219469 T DE60219469 T DE 60219469T DE 60219469 D1 DE60219469 D1 DE 60219469D1
Authority
DE
Germany
Prior art keywords
antibiotics
preparation
heterocyclic compounds
heterocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219469T
Other languages
English (en)
Other versions
DE60219469T2 (de
Inventor
Joseph Aszodi
Maxime Lampilas
Branislav Musicki
David Alan Rowlands
Pascal Collette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novexel SA
Original Assignee
Novexel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novexel SA filed Critical Novexel SA
Publication of DE60219469D1 publication Critical patent/DE60219469D1/de
Application granted granted Critical
Publication of DE60219469T2 publication Critical patent/DE60219469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60219469T 2001-06-08 2002-06-04 Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika Expired - Lifetime DE60219469T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0107520 2001-06-08
FR0107520A FR2825705B1 (fr) 2001-06-08 2001-06-08 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
PCT/FR2002/001877 WO2002100860A2 (fr) 2001-06-08 2002-06-04 Composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Publications (2)

Publication Number Publication Date
DE60219469D1 true DE60219469D1 (de) 2007-05-24
DE60219469T2 DE60219469T2 (de) 2007-11-29

Family

ID=8864102

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219469T Expired - Lifetime DE60219469T2 (de) 2001-06-08 2002-06-04 Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika

Country Status (15)

Country Link
US (2) US7288549B2 (de)
EP (2) EP1399444B1 (de)
JP (1) JP4509551B2 (de)
AR (1) AR036091A1 (de)
AT (1) ATE359286T1 (de)
CA (1) CA2449830C (de)
CY (1) CY1106801T1 (de)
DE (1) DE60219469T2 (de)
DK (1) DK1399444T3 (de)
ES (1) ES2284938T3 (de)
FR (1) FR2825705B1 (de)
IL (1) IL158756A0 (de)
MX (1) MXPA03011039A (de)
PT (1) PT1399444E (de)
WO (1) WO2002100860A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
EP1904069B1 (de) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
EP2077262A4 (de) * 2006-10-23 2011-12-28 Takeda Pharmaceutical Iminopyridinderivate und deren verwendung
FR2914923B1 (fr) * 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
FR2916444B1 (fr) * 2007-05-25 2011-02-11 Sanofi Aventis Procede de preparation de n-carboxyanhydride enantiomeriquement enrichi.
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
PT2231667E (pt) 2008-01-18 2013-12-13 Merck Sharp & Dohme Inibidores de beta-lactamase
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CL2009000964A1 (es) * 2008-04-23 2010-03-26 Takeda Pharmaceuticals Co Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012092530A1 (en) 2010-12-30 2012-07-05 Vanderbilt University Naphthyridinone analogs as mglur5 positive allosteric modulators
WO2012097182A1 (en) * 2011-01-12 2012-07-19 Vanderbilt University Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mglur5 modulators
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
JP5881514B2 (ja) * 2012-04-09 2016-03-09 株式会社トクヤマ アミン誘導体の製造方法
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CN103910676B (zh) * 2013-01-04 2015-11-18 华东师范大学 一种多取代四氢异喹啉衍生物的合成方法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
WO2015046207A1 (ja) 2013-09-24 2015-04-02 Meiji Seikaファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
SG11201602723RA (en) 2013-10-08 2016-05-30 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
WO2016081452A1 (en) * 2014-11-17 2016-05-26 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
CN107438614B (zh) * 2015-04-03 2020-01-31 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3075381A1 (de) * 2015-04-03 2016-10-05 Mutabilis Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
EP3184529A1 (de) 2015-12-23 2017-06-28 Mutabilis Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
US10800778B2 (en) * 2016-09-16 2020-10-13 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3300736B1 (de) * 2016-09-30 2021-05-05 Mutabilis Zusammensetzung mit einer antibiotischen verbindung und heterocyclischen verbindung und deren verwendung bei der vorbeugung oder behandlung bakterieller infektionen
CN108239089B (zh) * 2016-12-27 2020-05-22 浙江医药股份有限公司新昌制药厂 一种阿维巴坦钠的合成方法
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
EP3357924A1 (de) * 2017-02-06 2018-08-08 Mutabilis Neuartige heterocyclische verbindungen und deren verwendung bei der vorbeugung oder behandlung von bakteriellen infektionen
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
CN109678855B (zh) 2017-10-18 2020-07-17 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN108276408B (zh) * 2018-04-19 2020-09-29 上海皓元医药股份有限公司 一种曲贝替定的中间体及其制备方法和用途
EP3604315A1 (de) * 2018-07-30 2020-02-05 Mutabilis Heterocyclische verbindungen und deren verwendung in der vorbeugung oder behandlung von bakteriellen infektionen
EP3604309A1 (de) 2018-07-30 2020-02-05 Mutabilis Heterocyclische verbindungen und deren verwendung in der vorbeugung oder behandlung von bakteriellen infektionen
CN111978321A (zh) * 2020-09-22 2020-11-24 海南梵圣生物科技有限公司 一种4-Boc-2,5,6,7-四氢吡唑并[4,3-b]吡啶及其衍生物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654282A (en) * 1969-08-21 1972-04-04 Houde Lab 1 2 3 4-tetrahydro-isoquinoline 1-carboxylic acids
US3629265A (en) * 1969-10-30 1971-12-21 Hoffmann La Roche 7-halo-4-isoquinolones
AU626427B2 (en) * 1989-06-09 1992-07-30 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
JPH05339263A (ja) * 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
EP1227103B1 (de) * 1993-09-29 2006-07-26 Nabi Ringerweiterte Nukleoside und Nukleotide
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) * 1995-12-22 1995-12-22 Astra Ab New Compounds
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
EP1070054A1 (de) * 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Aminverbindungen, ihre herstellung und ihre verwendung als somatostatin rezeptor antagonisten oder agonisten
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CN1285588C (zh) * 1998-12-18 2006-11-22 先灵公司 法尼基蛋白转移酶抑制剂
WO2001025228A1 (fr) * 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
AU2001246893A1 (en) * 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
WO2002051231A1 (en) * 2000-12-22 2002-07-04 Basf Aktiengesellschaft Genes of corynebacterium
US7179921B2 (en) * 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Also Published As

Publication number Publication date
EP1798231A3 (de) 2008-02-27
JP4509551B2 (ja) 2010-07-21
PT1399444E (pt) 2007-05-31
FR2825705A1 (fr) 2002-12-13
WO2002100860A2 (fr) 2002-12-19
CA2449830C (en) 2012-11-27
CY1106801T1 (el) 2012-05-23
US20070299108A1 (en) 2007-12-27
AR036091A1 (es) 2004-08-11
IL158756A0 (en) 2004-05-12
JP2005518333A (ja) 2005-06-23
EP1399444A2 (de) 2004-03-24
DE60219469T2 (de) 2007-11-29
MXPA03011039A (es) 2004-03-19
CA2449830A1 (en) 2002-12-19
US8148540B2 (en) 2012-04-03
ATE359286T1 (de) 2007-05-15
US20050245505A1 (en) 2005-11-03
FR2825705B1 (fr) 2005-05-20
EP1399444B1 (de) 2007-04-11
US7288549B2 (en) 2007-10-30
ES2284938T3 (es) 2007-11-16
EP1798231A2 (de) 2007-06-20
WO2002100860A3 (fr) 2003-11-20
DK1399444T3 (da) 2007-06-04

Similar Documents

Publication Publication Date Title
DE60219469D1 (de) Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika
DE50207522D1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE50312949D1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
DE50309807D1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE50113328D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE50111293D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE305456T1 (de) Bizyklische heterozyklen, diese verbindungen enthaltende zusammenstellungen,und verfahren zu deren herstellung
DE50110906D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE502004008951D1 (de) Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE50111799D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE50114874D1 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE60208373D1 (de) Polyaryleneether-polyolefinzusammensetzung, verfahren zu deren herstellung und formassen daraus
DE602004029236D1 (de) Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren
DE50300813D1 (de) Neue fluorencarbonsaureester, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE60100246D1 (de) Polyxylosidderivate, Verfahren zu deren Herstellung, Zusammensetzung und Verwendung als Tensid
DE502004002117D1 (de) Substituierte thiazol-benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
DE50313017D1 (de) Ringsubstituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE602004029245D1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE602004031165D1 (de) Arylvinylazacycloalkan-Verbindungen und Verfahren zu deren Herstellung und Verwendung
DE112004002104A5 (de) Hochtackige Klebmasse, Verfahren zu deren Herstellung und deren Verwendung
DE602004010229D1 (de) Polyenpolyketide, verfahren zu deren herstellung und deren verwendung als pharmazeutikum
DE60306693D1 (de) Heterozyklische Verbindungen enthaltende opthalmische Gegenstände und Verfahren zu deren Herstellung
DE50011179D1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10081263D2 (de) Schraubverbindung und Verbindungsmittel hierfür sowie Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition